381 related articles for article (PubMed ID: 31150711)
1. A randomized phase 3b/4 study to evaluate concomitant use of topical ivermectin 1% cream and doxycycline 40-mg modified-release capsules, versus topical ivermectin 1% cream and placebo in the treatment of severe rosacea.
Schaller M; Kemény L; Havlickova B; Jackson JM; Ambroziak M; Lynde C; Gooderham M; Remenyik E; Del Rosso J; Weglowska J; Chavda R; Kerrouche N; Dirschka T; Johnson S
J Am Acad Dermatol; 2020 Feb; 82(2):336-343. PubMed ID: 31150711
[TBL] [Abstract][Full Text] [Related]
2. Treatment of Rosacea With Concomitant Use of Topical Ivermectin 1% Cream and Brimonidine 0.33% Gel: A Randomized, Vehicle-controlled Study.
Gold LS; Papp K; Lynde C; Lain E; Gooderham M; Johnson S; Kerrouche N
J Drugs Dermatol; 2017 Sep; 16(9):909-916. PubMed ID: 28915286
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double-blind, vehicle-controlled pivotal studies.
Stein L; Kircik L; Fowler J; Tan J; Draelos Z; Fleischer A; Appell M; Steinhoff M; Lynde C; Liu H; Jacovella J
J Drugs Dermatol; 2014 Mar; 13(3):316-23. PubMed ID: 24595578
[TBL] [Abstract][Full Text] [Related]
4. Superiority of ivermectin 1% cream over metronidazole 0·75% cream in treating inflammatory lesions of rosacea: a randomized, investigator-blinded trial.
Taieb A; Ortonne JP; Ruzicka T; Roszkiewicz J; Berth-Jones J; Peirone MH; Jacovella J;
Br J Dermatol; 2015 Apr; 172(4):1103-10. PubMed ID: 25228137
[TBL] [Abstract][Full Text] [Related]
5. Superior Efficacy with Ivermectin 1% Cream Compared to Metronidazole 0.75% Cream Contributes to a Better Quality of Life in Patients with Severe Papulopustular Rosacea: A Subanalysis of the Randomized, Investigator-Blinded ATTRACT Study.
Schaller M; Dirschka T; Kemény L; Briantais P; Jacovella J
Dermatol Ther (Heidelb); 2016 Sep; 6(3):427-36. PubMed ID: 27432169
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness and safety of modified-release doxycycline capsules once daily for papulopustular rosacea monotherapy results from a large community-based trial in subgroups based on gender.
Del Rosso JQ; Preston NJ; Caveney SW; Gottschalk RW
J Drugs Dermatol; 2012 Jun; 11(6):703-7. PubMed ID: 22648216
[TBL] [Abstract][Full Text] [Related]
7. Long-term safety of ivermectin 1% cream vs azelaic acid 15% gel in treating inflammatory lesions of rosacea: results of two 40-week controlled, investigator-blinded trials.
Stein Gold L; Kircik L; Fowler J; Jackson JM; Tan J; Draelos Z; Fleischer A; Appell M; Steinhoff M; Lynde C; Sugarman J; Liu H; Jacovella J;
J Drugs Dermatol; 2014 Nov; 13(11):1380-6. PubMed ID: 25607706
[TBL] [Abstract][Full Text] [Related]
8. Topical Ivermectin 10 mg/g and Oral Doxycycline 40 mg Modified-Release: Current Evidence on the Complementary Use of Anti-Inflammatory Rosacea Treatments.
Steinhoff M; Vocanson M; Voegel JJ; Hacini-Rachinel F; Schäfer G
Adv Ther; 2016 Sep; 33(9):1481-501. PubMed ID: 27432381
[TBL] [Abstract][Full Text] [Related]
9. Improved clinical outcome and biomarkers in adults with papulopustular rosacea treated with doxycycline modified-release capsules in a randomized trial.
Di Nardo A; Holmes AD; Muto Y; Huang EY; Preston N; Winkelman WJ; Gallo RL
J Am Acad Dermatol; 2016 Jun; 74(6):1086-92. PubMed ID: 26951940
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of topical ivermectin and impact on quality of life in patients with papulopustular rosacea: A systematic review and meta-analysis.
Husein-ElAhmed H; Steinhoff M
Dermatol Ther; 2020 Jan; 33(1):e13203. PubMed ID: 31863543
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and safety of once-daily doxycycline capsules as monotherapy in patients with rosacea: an analysis by Fitzpatrick skin type.
Alexis AF; Webster G; Preston NJ; Caveney SW; Gottschalk RW
J Drugs Dermatol; 2012 Oct; 11(10):1219-22. PubMed ID: 23134987
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and safety of doxycycline 40 mg (30-mg immediate-release and 10-mg delayed-release beads) once daily as add-on therapy to existing topical regimens for the treatment of papulopustular rosacea: results from a community-based trial.
Del Rosso JQ
Cutis; 2010 Nov; 86(5 Suppl):16-25. PubMed ID: 21229827
[TBL] [Abstract][Full Text] [Related]
13. Combined effect of anti-inflammatory dose doxycycline (40-mg doxycycline, usp monohydrate controlled-release capsules) and metronidazole topical gel 1% in the treatment of rosacea.
Fowler JF
J Drugs Dermatol; 2007 Jun; 6(6):641-5. PubMed ID: 17668530
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness of Ivermectin 1% Cream in Adults with Papulopustular Rosacea in the United States.
Taieb A; Stein Gold L; Feldman SR; Dansk V; Bertranou E
J Manag Care Spec Pharm; 2016 Jun; 22(6):654-65. PubMed ID: 27231793
[TBL] [Abstract][Full Text] [Related]
15. Long-term inflammatory rosacea management with subantibiotic dose oral doxycycline 40 mg modified-release capsules once daily.
Del Rosso JQ; Brantman S; Baldwin H
Dermatol Ther; 2022 Jan; 35(1):e15180. PubMed ID: 34713539
[TBL] [Abstract][Full Text] [Related]
16. An open-label, community-based, 12-week assessment of the effectiveness and safety of monotherapy with doxycycline 40 mg (30-mg immediate-release and 10-mg delayed-release beads).
Webster GF
Cutis; 2010 Nov; 86(5 Suppl):7-15. PubMed ID: 21229826
[TBL] [Abstract][Full Text] [Related]
17. Maintenance of remission following successful treatment of papulopustular rosacea with ivermectin 1% cream vs. metronidazole 0.75% cream: 36-week extension of the ATTRACT randomized study.
Taieb A; Khemis A; Ruzicka T; Barańska-Rybak W; Berth-Jones J; Schauber J; Briantais P; Jacovella J; Passeron T;
J Eur Acad Dermatol Venereol; 2016 May; 30(5):829-36. PubMed ID: 26691278
[TBL] [Abstract][Full Text] [Related]
18. A community-based study of the effectiveness of doxycycline 40 mg (30-mg immediate-release and 10-mg delayed-release beads) on quality of life and satisfaction with treatment in participants with rosacea.
Baldwin HE
Cutis; 2010 Nov; 86(5 Suppl):26-36. PubMed ID: 21229828
[TBL] [Abstract][Full Text] [Related]
19. [Rosacea: New data for better care].
Cribier B
Ann Dermatol Venereol; 2017; 144(8-9):508-517. PubMed ID: 28728857
[TBL] [Abstract][Full Text] [Related]
20. A multicenter study of topical azelaic acid 15% gel in combination with oral doxycycline as initial therapy and azelaic acid 15% gel as maintenance monotherapy.
Thiboutot DM; Fleischer AB; Del Rosso JQ; Rich P
J Drugs Dermatol; 2009 Jul; 8(7):639-48. PubMed ID: 19588640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
